Menopause can accelerate age-related weight gain, increasing a woman’s odds of becoming overweight or obese, researchers said in background notes. The change of life also can cause symptoms like hot flashes and night sweats, for which hormone therapy is the most effective first-line treatment, researchers said.

Poison control calls involving GLP-1 medications like semaglutide and tirzepatide have dramatically risen in recent years.

Wegovy and Zepbound are two FDA-approved weight loss drugs. Learn how they compare in benefits, side effects, and more to decide which option suits you best.

By Gnaneshwar Rajan and Sriparna Roy Jan 30 (Reuters) - Regeneron Pharmaceuticals' executives voiced confidence in its experimental weight-loss drug on Friday, saying added cholesterol-lowering benefits could give the company an edge in an increasingly crowded obesity market.

Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the year in 2025. Ozempic isn’t the only drug that mimics the natural GLP-1 hormone,

Zepbound (tirzepatide) and Mounjaro (tirzepatide) are prescription drugs used to treat different conditions. Zepbound and Mounjaro are not available as generic drugs. The two drugs have some similarities and differences, such as side effects, uses, and ...

Ozempic, Mounjaro, and Zepbound can drive impressive weight loss, but stopping them is often followed by rapid weight regain. Researchers found that people regain weight faster after quitting these drugs than after diet and exercise alone.

Novo Nordisk (NVO) has spent nearly half a billion dollars promoting its GLP-1 drugs Wegovy and Ozempic in the U.S., beating Lilly (LLY), whose U.S. advertising spend for its rival medicines Zepbound and Mounjaro exceeded $200M,